285 related articles for article (PubMed ID: 37450935)
41. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
[TBL] [Abstract][Full Text] [Related]
42. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
43. Antibiotics for exacerbations of chronic obstructive pulmonary disease.
Vollenweider DJ; Frei A; Steurer-Stey CA; Garcia-Aymerich J; Puhan MA
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010257. PubMed ID: 30371937
[TBL] [Abstract][Full Text] [Related]
44. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
45. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
46. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.
Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Am J Respir Crit Care Med; 2017 May; 195(9):1189-1197. PubMed ID: 28278391
[TBL] [Abstract][Full Text] [Related]
47. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Herath SC; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
[TBL] [Abstract][Full Text] [Related]
49. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
50. Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial.
Vermeersch K; Belmans A; Bogaerts K; Gyselinck I; Cardinaels N; Gabrovska M; Aumann J; Demedts IK; Corhay JL; Marchand E; Slabbynck H; Haenebalcke C; Vermeersch S; Verleden GM; Troosters T; Ninane V; Brusselle GG; Janssens W;
Respir Res; 2019 Oct; 20(1):237. PubMed ID: 31665017
[TBL] [Abstract][Full Text] [Related]
51. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Trials; 2015 Jun; 16():267. PubMed ID: 26058585
[TBL] [Abstract][Full Text] [Related]
52. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
53. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Teo E; Lockhart K; Purchuri SN; Pushparajah J; Cripps AW; van Driel ML
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010010. PubMed ID: 28626902
[TBL] [Abstract][Full Text] [Related]
54. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
55. Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial.
Ritchie AI; Brill SE; Vlies BH; Finney LJ; Allinson JP; Alves-Moreira L; Wiseman DJ; Walker PP; Baker E; Elkin SL; Mallia P; Law M; Donaldson GC; Calverley PMA; Wedzicha JA
Am J Respir Crit Care Med; 2020 Aug; 202(4):549-557. PubMed ID: 32267724
[No Abstract] [Full Text] [Related]
56. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Sathananthan K; Fortescue R
Cochrane Database Syst Rev; 2019 May; 5(5):CD001287. PubMed ID: 31107966
[TBL] [Abstract][Full Text] [Related]
57. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
58. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.
Bafadhel M; Greening NJ; Harvey-Dunstan TC; Williams JE; Morgan MD; Brightling CE; Hussain SF; Pavord ID; Singh SJ; Steiner MC
Chest; 2016 Aug; 150(2):320-8. PubMed ID: 26851799
[TBL] [Abstract][Full Text] [Related]
59. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial.
Jenkins CR; Wen FQ; Martin A; Barnes PJ; Celli B; Zhong NS; Zheng JP; Scaria A; Di Tanna GL; Bradbury T; Berend N;
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334939
[TBL] [Abstract][Full Text] [Related]
60. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
